Dianthus Therapeutics, Inc. (DNTH) analyst actions
Rating and price-target actions on DNTH in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the DNTH overview →
3 measured DNTH analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis | Press release | +0.16% | -0.39% | |
| Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) | Press release | +0.20% | -1.80% | |
| Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) | Press release | +0.98% | +3.58% |
Keep exploring
More DNTH: earnings → · SEC filings → · DNTH overview →